Introduction: A Targeted Approach to Valvular Health

Lipoprotein(a), often abbreviated as Lp(a), is a well-established and independent risk factor for cardiovascular diseases. Recent clinical insights suggest that the relationship between aspirin and lipoprotein(a) may hold the key to preventing calcific aortic valve disease (CAVD). While previous guidelines have pulled back on routine aspirin use for primary prevention, specific high-risk subgroups might still derive significant benefits.

The Multi-Ethnic Study of Atherosclerosis (MESA) recently explored whether regular aspirin use impacts the development of aortic valve calcium (AVC) and severe aortic stenosis (AS). Interestingly, the results indicate that the benefit of aspirin is highly dependent on an individual\'s lipid profile, particularly their Lp(a) levels.

Key Findings from the MESA Analysis

Researchers analyzed data from over 6,500 participants with a median follow-up of nearly 17 years for severe aortic stenosis. The study defined regular aspirin use as taking the medication at least three days per week. The results showed a dramatic reduction in risk for those with elevated Lp(a) levels.

• AVC Risk Reduction: For individuals with Lp(a) \u226575 mg/dL, regular aspirin use was associated with a 58% lower risk of incident AVC. This risk reduction improved to 83% for those with Lp(a) \u2265100 mg/dL.


• Severe AS Prevention: The impact on severe aortic stenosis was even more profound. In patients with Lp(a) \u226575 mg/dL, aspirin use was associated with a staggering 98% reduction in the risk of developing severe AS.


• The LDL-C Contrast: Notably, the study found no such association for participants with elevated LDL cholesterol. This suggests that aspirin\'s protective mechanism in this context is specific to the pathways influenced by Lp(a).

Why Does Aspirin and Lipoprotein(a) Interaction Matter?

Lp(a) contains a unique protein called apolipoprotein(a), which shares a structural similarity with plasminogen. This similarity gives Lp(a) pro-thrombotic and anti-fibrinolytic properties, which contribute to both atherosclerosis and valvular calcification. Consequently, aspirin\'s antiplatelet effects likely counteract these specific pro-thrombotic mechanisms.

Furthermore, because Lp(a) levels are largely determined by genetics rather than lifestyle, many patients remain at high risk despite statin therapy. These findings provide a potential pharmacological strategy for a population that currently has very few targeted treatment options.

Clinical Implications for Practice

While these results are from an exploratory analysis of observational data, they underscore the importance of personalized medicine. Clinicians should consider measuring Lp(a) levels to better stratify cardiovascular risk. For patients with significantly elevated Lp(a), a tailored discussion regarding the benefits of regular aspirin use versus the risk of bleeding is warranted. However, confirmatory randomized controlled trials are still necessary to solidify these findings into standard clinical guidelines.

Frequently Asked Questions

How often should aspirin be taken to see these benefits?

In the MESA study, regular aspirin use was defined as taking the medication at least three days per week. However, the exact optimal dose for valvular protection remains a subject for further clinical investigation.

Does aspirin help if my LDL-C is high but my Lp(a) is normal?

No, the study specifically found no association between aspirin use and reduced risk of aortic valve calcification in participants with high LDL-C but normal Lp(a) levels. In those cases, traditional lipid-lowering therapies remain the priority.

Should everyone with high Lp(a) start taking aspirin?

While the study shows a strong association with reduced risk, the decision to start aspirin must be individualized. Doctors must weigh the potential for reduced valvular and cardiovascular risk against the risk of gastrointestinal or intracranial bleeding.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional relationship between the reader and the author. Always seek the advice of a qualified healthcare provider regarding any medical condition or treatment. Refer to the latest local and national guidelines for clinical practice.

References

Razavi AC et al. Aspirin use, lipoprotein(a), and calcific aortic valve disease: the Multi-ethnic Study of Atherosclerosis. Eur Heart J. 2026 Feb 21. doi: undefined. PMID: 41721439.

Bhatia H et al. Aspirin Use and the Risk of Coronary Heart Disease Events in Individuals With Elevated Lipoprotein(a). J Am Coll Cardiol. 2024;83(1):15-25.

American College of Cardiology. Lipoprotein(a) and Aspirin in Primary Prevention: A New Perspective. July 17, 2024.